Genmab A/S (GNMSF) Net Income towards Common Stockholders (2018 - 2026)

Genmab A (GNMSF) has 6 years of Net Income towards Common Stockholders data on file, last reported at $5.7 billion in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 7.29% year-over-year to $5.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 billion (up 14.15% YoY) and the FY2025 annual result came in at $963.0 million, down 81.25% from the prior year.
• Net Income towards Common Stockholders fell to $5.7 billion in Q1 2026, from $5.8 billion in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $5.8 billion in Q3 2025 to a low of -$2.9 million in Q4 2024.
• A 3-year average of $3.4 billion and a median of $4.8 billion in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders soared 34.43% — and 2026, when it advanced 7.29%.
• Tracing GNMSF's Net Income towards Common Stockholders over 3 years: stood at -$2.9 million in 2024, then surged by 197728.87% to $5.8 billion in 2025, then declined by 1.2% to $5.7 billion in 2026.
• The last three Net Income towards Common Stockholders figures came in at $5.7 billion (Q1 2026), $5.8 billion (Q3 2025), and $531.0 million (Q2 2025), per Business Quant data.